Kinetensin (human)
(Synonyms: 升压素,Kinetensin (human)) 目录号 : GC14971A peptide
Cas No.:103131-69-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | Rat peritoneal mast cells are incubated with kinetensin at 37°C for 10 min. The incubation is stopped by the addition of 1.8 mL of ice-cold buffered saline and cells are separated from supernatant by centrifugation. Histamine release is expressed as per cent of total mast cell histamine[2]. |
Animal experiment: | Rats[2]Anesthetized Sprague-Dawley rats are given 25I-albumin i.v. Samples are then injected intradermally in 5x2 spots on the back and comprised saline as a control or kinetensin in different doses in 100 μL saline. After 20 rain, skin biopsies of 7 mm diameter are cut out, weighed and transferred to a gamma-counter. Results are expressed as: (counts per min (cpm) in tissue per gram wet weight/cpm in plasma per mL plasma)[2]. |
References: [1]. Mogard MH, et al. The amino acid sequence of kinetensin, a novel peptide isolated from pepsin-treated human plasma: homology with human serum albumin, neurotensin and angiotensin. Biochem Biophys Res Commun. 1986 May 14;136(3):983-8. |
Kinetensin is a neurotensin-like peptide isolated from pepsin-treated human plasma.
The peptide kinetensin isolated from pepsin-treated human plasma induces a dose-dependent release of histamine when exposed to rat peritoneal mast cells. The threshold concentration is around 1 μM, the ED50 is 10 μM, and the optimal concentration of between 100 to 1000 μM released 80% of the total histamine. Kinetensin is 10 to 100 times less potent than neurotensin and equipotent with the opioid peptide dynorphin. The histamine release is clearly temperature-dependent, with no release occurring at 0 or 45 °C and with an optimum around 37 °C. The histamine release is significantly reduced in the absence of extracellular calcium[2].
Kinetensin also induces a dose-dependent increase in vascular permeability when injected intradermally into rats[2].
References:
[1]. Mogard MH, et al. The amino acid sequence of kinetensin, a novel peptide isolated from pepsin-treated human plasma: homology with human serum albumin, neurotensin and angiotensin. Biochem Biophys Res Commun. 1986 May 14;136(3):983-8.
[2]. Sydbom A, et al. Stimulation of histamine release by the peptide kinetensin. Agents Actions. 1989 Apr;27(1-2):68-71.
Cas No. | 103131-69-7 | SDF | |
别名 | 升压素,Kinetensin (human) | ||
分子式 | C56H85N17O11 | 分子量 | 1172.39 |
溶解度 | Soluble to 2 mg/ml in Water | 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.853 mL | 4.2648 mL | 8.5296 mL |
5 mM | 0.1706 mL | 0.853 mL | 1.7059 mL |
10 mM | 0.0853 mL | 0.4265 mL | 0.853 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。